Cited 5 times in
High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 정규식 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2020-12-01T17:08:23Z | - |
dc.date.available | 2020-12-01T17:08:23Z | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/180140 | - |
dc.description.abstract | Long-term suppression of hepatitis B virus with tenofovir (TDF) induces fibrosis regression, and repeated liver stiffness (LS) measurement can indicate the improvement of fibrosis. We aimed to investigate predictors for LS improvement assessed by changes in patients receiving long-term TDF therapy in chronic hepatitis B (CHB) with liver cirrhosis. CHB patients with histologically proven liver cirrhosis who received TDF as the first-line therapy from 2012 to 2015 were recruited. LS and controlled attenuation parameter (CAP) measurements were repeated at baseline and 3 years after therapy. Liver stiffness improvement was defined as a drop of LS value ≥30% from the baseline. A total of 131 patients were enrolled (mean age 51.4% and male 64.9%). After 3 years of TDF therapy, the mean LS value significantly improved (from 14.7 to 8.6 kPa, P < .001), and 96 (73.3%) patients have achieved LS improvement. Predictors associated with improvement of LS were low body mass index (BMI), HBeAg positivity, and low CAP value at baseline. In multivariate analysis, low BMI was a single factor independently associated with LS improvement (odds ratio 0.680, 95% CI 0.560-0.825, P < .001). Patients with BMI < 23.5, had a 1.96 times more chance of achieving LS improvement compared to those with BMI ≥ 23.5 (90.1% vs. 46.0%, P = .001). High BMI was a single significant factor hindering the fibrosis improvement in patients receiving long-term TDF therapy in CHB with liver cirrhosis. Life style modification and BMI reduction should be encouraged to enhance fibrosis improvement. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Young Eun Chon | - |
dc.contributor.googleauthor | Kyu Sik Jung | - |
dc.contributor.googleauthor | Yeonjung Ha | - |
dc.contributor.googleauthor | Mi Na Kim | - |
dc.contributor.googleauthor | Joo Ho Lee | - |
dc.contributor.googleauthor | Seong Gyu Hwang | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.identifier.doi | 10.1111/jvh.13345 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03578 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 32558181 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13345 | - |
dc.subject.keyword | body mass index | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | fibrosis improvement | - |
dc.subject.keyword | liver stiffness | - |
dc.subject.keyword | tenofovir | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 정규식 | - |
dc.contributor.affiliatedAuthor | 한광협 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1119 | - |
dc.citation.endPage | 1126 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.27(11) : 1119-1126, 2020-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.